Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hematologic Indices and Chronic Subdural Hematoma: A Single-Center Cohort Study.
Asian J Neurosurg
December 2024
Department of Neurosurgery, University Hospital Center Zagreb, Zagreb, Croatia.
Article Synopsis
- Chronic subdural hematoma (cSDH) primarily affects older adults, is often recurrent after treatment, and can lead to severe complications, including death, with inflammation playing a significant role in its development.
- The study analyzed cases of cSDH operated on between 2018 and 2020 by reviewing data on sociodemographics, clinical factors, laboratory indices, and treatment outcomes, focusing on their association with the thickness of the cSDH.
- Out of 72 patients studied, most were elderly with common chronic conditions, and the research found a median Glasgow Outcome Score (GOS) of 5 at discharge and 1 year, with notable rates of recurrence and resurgery occurring within a year post-treatment
Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy.
World J Hepatol
November 2024
Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome 00185, Italy.
Hepatic encephalopathy (HE) is one of the main complications of cirrhosis, characterized by a wide spectrum of neuropsychiatric alterations that lead to an increase in mortality, morbidity and recurrent hospitalizations. Due to the central role in HE pathogenesis of ammonia and other neurotoxins primarily produced by the gut microbiota, the main therapeutic approaches for the treatment of HE are based on the modulation of the gut microbiota. Rifaximin is a non-absorbable broad-spectrum antibiotic, that is effective against ammonia-producing gram-positive, gram-negative, and anaerobic species, approved for the treatment of HE in secondary prophylaxis.
View Article and Find Full Text PDFTraditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial.
Lancet
November 2024
Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry of Education, Shanghai, China. Electronic address:
Background: There are few proven treatments for acute spontaneous intracerebral haemorrhage, and they all target reducing expansion of the haematoma. The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao) in an oral solution is comprised of several Chinese herbs that are widely used to treat patients with intracerebral haemorrhage in China on the understanding that they enhance resorption of the haematoma and reduce neuroinflammation. We aimed to provide a reliable assessment of the safety and efficacy of FYTF-919 in patients with moderate to severe acute intracerebral haemorrhage.
View Article and Find Full Text PDFDiphenhydramine Overdose: A Case Report and Topic Review of Prehospital Diagnosis and Treatment.
Cureus
October 2024
Emergency Medicine, Florida State University College of Medicine, Sarasota, USA.
Diphenhydramine (DPH), a readily available first-generation H1 receptor antihistamine, can have severe consequences when taken in excessive amounts and can lead to grave outcomes such as seizures, dysrhythmias, coma, and death. Recognizing the early signs and symptoms of DPH toxicity is crucial. Fortunately, fatal adult cases of DPH overdose are rare.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!